Passage BIO Files 8-K

Ticker: PASG · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1787297

Sentiment: neutral

Topics: 8-K, SEC Filing, Disclosure

TL;DR

Passage BIO filed a routine 8-K, no major news.

AI Summary

Passage BIO, Inc. filed an 8-K on October 24, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form type.

Why It Matters

This 8-K filing indicates Passage BIO, Inc. is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — This filing is a standard 8-K for reporting disclosures and exhibits, not indicating any specific new risks or material events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Passage BIO, Inc.?

The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated by the filing's item information.

On what date was this 8-K report filed?

The 8-K report was filed on October 24, 2024.

What is Passage BIO, Inc.'s state of incorporation?

Passage BIO, Inc. is incorporated in Delaware.

What is the business address of Passage BIO, Inc.?

The business address is One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, PA 19103.

Does this filing indicate any specific new financial results or material events?

No, this filing primarily serves as a notification of standard reporting items (Regulation FD Disclosure, Financial Statements and Exhibits) and does not detail specific new financial results or material events within the provided text.

Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-10-24 07:00:15

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 24, 2024, Passage Bio, Inc. (the " Company ") presented a scientific presentation at the European Society of Gene & Cell Therapy 31st Annual Congress (the " ESGCT Presentation "). The Company also issued a press release on October 24, 2024, related to the ESGCT Presentation. A copy of the press release and ESGCT Presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the " Securities Act "). The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Passage Bio, Inc. press release dated October 24, 2024 99.2 ESGCT Presentation 104 Cover Page Interactive Data File (formatted as Inline XBRL). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASSAGE BIO, INC. Date: October 24, 2024 By: /s/ Kathleen Borthwick Kathleen Borthwick Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing